Outcome after discontinuing antiviral agents during pregnancy in women infected with hepatitis B virus

Journal of Clinical Virology

Volumn 56, Issue 4, 2013, Pages 299-305

  Kim, Hee Yeon ^a   Choi, Jong Young ^a   Park, Chung Hwa ^a   Jang, Jeong Won ^a   Kim, Chang Wook ^a   Bae, Si Hyun ^a   Yoon, Seung Kew ^a   Yang, Jin Mo ^a   Lee, Chang Don ^a   Lee, Young Sok ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Antiviral agents; Cessation; Hepatitis B virus; Pregnancy

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; ENTECAVIR; LAMIVUDINE; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; DECOMPENSATED LIVER CIRRHOSIS; DELIVERY; DISEASE ACTIVITY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG WITHDRAWAL; FEMALE; GESTATIONAL AGE; HEPATITIS B; HEPATITIS B VIRUS; HIGH RISK PATIENT; HUMAN; MATERNAL AGE; OUTCOME ASSESSMENT; PREDICTION; PREGNANCY; PREGNANT WOMAN; PRIORITY JOURNAL; PUERPERIUM; REBOUND; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION; TREATMENT WITHDRAWAL; VIRUS LOAD;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; POSTPARTUM PERIOD; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84875093200     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2012.11.019     Document Type: Article

References (22)

1. Chen C.J., Wang L.Y., Yu M.W. Epidemiology of hepatitis B virus infection in the Asia-Pacific region. J Gastroenterol Hepatol 2000, 15(Suppl.):E3-E6.
2. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004, 11:97-107.
3. Alter M.J. Epidemiology of hepatitis B in Europe and worldwide. J Hepatol 2003, 39(Suppl. 1):S64-S69.
4. Sinha S., Kumar M. Pregnancy and chronic hepatitis B virus infection. Hepatol Res 2010, 40:31-48.
5. Su G.G., Pan K.H., Zhao N.F., Fang S.H., Yang D.H., Zhou Y. Efficacy and safety of lamivudine treatment for chronic hepatitis B in pregnancy. World J Gastroenterol 2004, 10:910-912.
6. Honkoop P., de Man R.A., Niesters H.G., Zondervan P.E., Schalm S.W. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology 2000, 32:635-639.
7. Söderström A., Norkrans G., Lindh M. Hepatitis B virus DNA during pregnancy and post partum: aspects on vertical transmission. Scand J Infect Dis 2003, 35:814-819.
8. ter Borg M.J., Leemans W.F., de Man R.A., Janssen H.L. Exacerbation of chronic hepatitis B infection after delivery. J Viral Hepat 2008, 15:37-41.
9. Chisari F.V., Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995, 13:29-60.
10. Aluvihare V.R., Kallikourdis M., Betz A.G. Regulatory T cells mediate maternal tolerance to the fetus. Nat Immunol 2004, 5:266-271.
11. Wegmann T.G., Lin H., Guilbert L., Mosmann T.R. Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon?. Immunol Today 1993, 14:353-356.
12. Stoop J.N., van der Molen R.G., Baan C.C., van der Laan L.J., Kuipers E.J., Kusters J.G., et al. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology 2005, 41:771-778.
13. Trowsdale J., Betz A.G. Mother's little helpers: mechanisms of maternal-fetal tolerance. Nat Immunol 2006, 7:241-246.
14. Marinos G., Naoumov N.V., Williams R. Impact of complete inhibition of viral replication on the cellular immune response in chronic hepatitis B virus infection. Hepatology 1996, 24:991-995.
15. Maruyama T., Iino S., Koike K., Yasuda K., Milich D.R. Serology of acute exacerbation in chronic hepatitis B virus infection. Gastroenterology 1993, 105:1141-1151.
16. Dienstag J.L., Schiff E.R., Wright T.L., Perrillo R.P., Hann H.W., Goodman Z., et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999, 341:1256-1263.
17. Lim S.G., Wai C.T., Rajnakova A., Kajiji T., Guan R. Fatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B. Gut 2002, 51:597-599.
18. Lee H.C., Suh D.J., Ryu S.H., Kim H., Shin J.W., Lim Y.S., et al. Quantitative polymerase chain reaction assay for serum hepatitis B virus DNA as a predictive factor for post-treatment relapse after lamivudine induced hepatitis B e antigen loss or seroconversion. Gut 2003, 52:1779-1783.
19. Lee H.W., Lee H.J., Hwang J.S., Sohn J.H., Jang J.Y., Han K.J., et al. Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B. Hepatology 2010, 51:415-421.
20. Wang L., Liu F., Liu Y.D., Li X.Y., Wang J.B., Zhang Z.H., et al. Stringent cessation criterion results in better durability of lamivudine treatment: a prospective clinical study in hepatitis B e antigen-positive chronic hepatitis B patients. J Viral Hepat 2010, 17:298-304.
21. Stevens C.E., Beasley R.P., Tsui J., Lee W.C. Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med 1975, 292:771-774.
22. Pol S., Corouge M., Fontaine H. Hepatitis B virus infection and pregnancy. Clin Res Hepatol Gastroenterol 2011, 35:618-622.